
Black Diamond Therapeutics, Inc.
BDTXHealthcare|Biotechnology|US
$1.74
+0.07 (+4.52%)
DCF Value
$10.92
Tangible Book / Share
$1.68
Cash / Share
$1.93
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Nov 13, 2025 (S-3). Possible dilution.
Upcoming Data Readouts (1)
Nov 2028
Est. completion
P2Glioblastoma (GBM)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566n=162
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2025
P1P2
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290Recent Press Releases
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Sep 2, 2026 · GlobeNewsWire
SEC Filings (37)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Aug 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 5, 2026 | 8-K | Material event | DocumentIndex |
| Jul 27, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jul 8, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jun 29, 2026 | 8-K | Material event | DocumentIndex |
| May 21, 2026 | 8-K | Material event | DocumentIndex |
| May 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| Apr 29, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 29, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 29, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 16, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Mar 16, 2026 | 10-K | Annual report | DocumentIndex |
| Mar 16, 2026 | 8-K | Material event | DocumentIndex |
| Feb 17, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Dec 3, 2025 | EFFECT | DocumentIndex | |
| Dec 3, 2025 | 8-K | Material event | DocumentIndex |
| Nov 13, 2025 | S-3 | Shelf registration | DocumentIndex |
| Nov 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 6, 2025 | 8-K | Material event | DocumentIndex |
| Aug 7, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 7, 2025 | 8-K | Material event | DocumentIndex |
| Jun 12, 2025 | 8-K | Material event | DocumentIndex |
| May 12, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 12, 2025 | 8-K | Material event | DocumentIndex |
| Apr 29, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Apr 18, 2025 | ARS | Annual report to holders | DocumentIndex |
| Apr 18, 2025 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 18, 2025 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 21, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 19, 2025 | 8-K | Material event | DocumentIndex |
| Mar 6, 2025 | S-8 | Employee stock plan | DocumentIndex |
| Mar 6, 2025 | 10-K | Annual report | DocumentIndex |
| Mar 6, 2025 | 8-K | Material event | DocumentIndex |
| Feb 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 14, 2024 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 14, 2024 | SC 13G | Passive 5%+ stake | DocumentIndex |